Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-04
2005-10-04
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S314000, C514S444000, C546S173000, C549S059000, C549S371000
Reexamination Certificate
active
06951882
ABSTRACT:
Urea-containing, substituted 4-phenyl-[1,3]-dioxanes, methods of manufacturing them, compositions containing them, and methods of using them to treat, for example, obesity or a sleep/wake disorder mediated by orexin-2 are described.
REFERENCES:
PCT International Search Report, dated May 12, 2004, for PCT Int'l. Appln. No. PCT/US03/40136.
Alo, B.I. et al. Sequential Directed Ortho Metalation-Boronic Acid Cross Coupling Reactions. A General Regiospecific Route to Oxygenated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid. J. Org. Chem. 1991, 56:3763-3768.
Ammoun, S. et al. Distinct Recognition of OX1 and OX2 Receptors by Orexin Peptides. J. Pharmacol. Exp. Ther. 2003, 305(2):507-514.
Blanco, M. et al. Cellular Localization of Orexin Receptors in Human Pituitary. J. Clin. Endocrinol. Metab. 2001, 86(4):1616-1619.
Chemelli, R.M. et al. Narcolepsy in Orexin Knockout Mice: Molecular Genetics and Sleep Regulation. Cell 1999, 98(4):437-451.
Chen, C.-T.et al. Pressor Effects of Orexins Injected Intracisternally and to Rostral Ventrolateral Medulla of Anesthetized Rats. Am. J. Physiol. 2000, 278(3):R692-R697.
Drouot, X. et al. Low Levels of Ventricular CSF Orexin/Hypocretin in Advanced PD. Neurology 2003, 61(4):540-543.
Fults, D. et al. Establishment and Characterization of a Human Primitive Neuroectodermal Tumor Cell Line from the Cerebral Hemisphere. J. Neuropathol. Exp. Neurol. 1992, 51(3):272-280.
Hara, J. Genetic Ablation of Orexin Neurons in Mice Results in Narcolepsy, Hypophagia, and Obesity. Neuron 2001, 30(2):345-354.
Kirchgessner, A.L. and M.-T. Liu. Orexin Synthesis and Response in the Gut. Neuron 1999, 24(4):941-951.
Larsson, K.P. et al. The STC-1 Cells Express Functional Orexin-A Receptors Coupled to CCK Release. Biochem. Biophys. Res. Commun. 2003, 309(1):209-216.
Lin, L. et al. The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) 2 Receptor Gene. Cell 1999, 98(3):365-376.
Lubkin, M. and A. Stricker-Krongrad. Independent Feeding and Metabolic Actions of Orexins in Mice. Biochem. Biophys. Res. Commun. 1998, 253(2):241-245.
Mignot, E. et al. Complex HLA-DR and -DQ Interactions Confer Risk of Narcolepsy-Cataplexy in Three Ethnic Groups. Am. J. Hum. Genet. 2001, 68(3):686-699.
Mignot, E. and E. Thorsby, Narcolepsy and the HLA System. N. Engl. J. Med. 2001, 344(9):692.
Miyaura, N. and A. Suzuki. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds: Chem. Rev. 1995, 95:2457-2483.
Nakamura, T. et al. Orexin-Induced Hyperlocomotion and Stereotypy Are Mediated by the Dopaminergic System. Brain Res. 2000, 873(1):181-187.
Nordin, I.C. and J.A. Thomas. An Improved Synthesis of (4S,5S)-2,2-Dimethyl-4-phenyl-1,3-dioxan-4-amine. Tetrahedron Lett. 1984, 25(50):5723-5724.
Peyron, C. et al. Neurons Containing Hypocretin (Orexin) Project to Multiple Neuronal Systems. J. Neurosci. 1998, 18(23):9996-10015.
Peyron, C. et al. A Mutation in a Case of Early Onset Narcolepsy and a Generalized Absence of Hypocretin Peptides in Human Narcoleptic Brains. Nat. Med. 2000, 6(9):991-997.
Piper, D.C. et al. The Novel Brain Neuropeptide, Orexin-A, Modulates the Sleep-Wake Cycle of Rats. Eur. J. Neurosci. 2000, 12(2):726-730.
Sakurai, T. et al. Orexin and Orexin Receptors: A Family of Hypothalamic and G Protein-Coupled Receptors that Regulate Feeding Behavior. Cell 1998, 92(4):573-585.
Samson, W.K. et al. Cardiovascular Regulatory Actions of the Hypocretins in Brain. Brain Res. 1999, 831(1-2):248-253.
Shirasaka, T. et al. Sympathetic and Cardiovascular Actions of Orexins in Conscious Rats. Am. J. Physiol. 1999, 277(6, Pt.2):R1780-R1785.
Takahashi, N. et al. Stimulation of Gastric Acid Secretion of Centrally Administered Orexin-A in Conscious Rats. Biochem. Biophys. Res. Commun. 1999, 254(3):623-627.
Van Den Pol, A.N. Hypothalamic Hypocretin (Orexin): Robust Innervation of the Spinal Cord. J. Neurosci. 1999, 19(8):3171-3182.
Willie, J.T. et al. Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice: Molecular Genetic Dissection of Non-REM and REM Sleep Regulatory Processes. Neuron 2003, 38(5):715-730.
Yamanaka, A. et al. Orexins Activate Histaminergic Neurons via the Orexin 2 Receptor. Biochem. Biophys. Res. Commun. 2002, 290(4):1237-1245.
Morie, Toshiya et al., “Convenient Synthesis of N-(2, 2-Dimethyl-1,3-Dioxan-5-YL)1H-Indazol E-3-Carboxamide”, Synthetic Communications, vol. 27, No. 4, pp. 559-566, 1997.
Comgenex Product List, Database Chemcats 'Online!, Chemical Abstracts Service, Order Nos. CGX-0377921, CGX-0377920, CGX-0145248Columbus, Ohio.
Carruthers Nicholas I
Jones Todd K.
Li Xiaobing
Lovenberg Timothy W.
McAtee Laura C.
Dentz Bernard
Janssen Pharmaceutica N.V.
LandOfFree
Substituted 4-phenyl-[1,3]-dioxanes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-phenyl-[1,3]-dioxanes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-phenyl-[1,3]-dioxanes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463939